Osteoarthritis Initiative

Launched in 2002 and completed in 2015, the Osteoarthritis Initiative (OAI) represents a collaboration of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute on Aging (NIA) and the private sector, who worked together to improve the efficiency of drug development and clinical trials for the treatment of osteoarthritis (OA). The study created a public access research resource that enables the worldwide scientific community to examine and analyze knee radiographs, X-rays and MRIs and a variety of other clinical data to better predict the progression of OA and develop new treatments to slow progression of or modify this disabling disease. The most common form of arthritis, osteoarthritis affects more than 30 million adults in the United States.

Among the many research efforts made possible by this resource is the FNIH Biomarkers Consortium Osteoarthritis Biomarkers Project, which is working to determine what biomarkers have greater prognostic ability to measure early progression of structural and symptomatic changes in knee osteoarthritis over time and predict treatment response.

Following the success of this project, the Biomarkers Consortium is in the preliminary stages of undertaking a new project PROGRESS OA – Clinical Evaluation and Qualification of Osteoarthritis Biomarkers. The goal of PROGRESS OA is to clinically validate these biomarkers, enabling their use as clinical endpoints, prognostic markers of disease progression and predictive markers of treatment response.

Goals

  • Create a public access research resource that enables the worldwide scientific community to examine and to analyze knee radiographs, X-rays and MRIs and a variety of other clinical data to better predict the progression of osteoarthritis.
  • Develop new treatments to slow progression of or modify osteoarthritis.

Results & Accomplishments

Data Access

The Osteoarthritis Initiative Data Release

Media

NIH Press Releases

Partners

GlaxoSmithKline
Merck Sharp & Dohme, Inc.
National Institute on Aging (NIA)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Novartis
Pfizer Inc